Dr. David Berry
Dave Berry was awarded a PhD from Surrey University in 1982 and is a Fellow of the Royal College of Pathologists. In 1967 he commissioned the new Medical Toxicology Unit laboratory (MTL) and brought it to operational readiness initially developing methods to detect and determine drugs and poisons in biological fluids and provide a service for identification and measurement of the increasing range of drugs encountered in self-poisoning. Dave subsequently developed procedures for detecting abused drugs in the urine of dependent patients and in 1969 he started to develop sensitive assays for some therapeutic drugs e.g. anticonvulsants, cardioactives, antidepressants. These assays were used to investigate the value of measuring drug concentrations in plasma to assist optimization of patient treatment and until recently these procedures provided the basis of a comprehensive TDM service. Dave was Consultant Clinical Scientist in the TDM section of MTL until December 2010 where he specialised in the management of epilepsy with the help of measured drug levels. In 2011 he was appointed Honary Consultant Scientist at the Epilepsy Society. His main interests are analytical method development, its application to investigate drug pharmacokinetics and subsequent extension into patient management. Dave has published almost 100 peer reviewed papers and invited articles; he has also produced numerous posters and given oral presentations at International/National Congresses. He is an on the editorial board of Epilepsia and TDM; he also referees papers for several other journals. Dave has undertaken numerous conjoint projects with various clinical and academic groups; he has supervised and examined a number of PhDs and other research degrees. He is also a visiting lecturer at several UK/overseas Universities and a member of several Professional bodies including ILAE, BPS, IATDMCT, ACB, RSC, FSS (MFSSoc), TIAFT, and AACC (including TDM/Toxicology division).